We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Retrospective Study of COVID-19 Treatments

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04949230
Recruitment Status : Recruiting
First Posted : July 2, 2021
Last Update Posted : September 5, 2021
Sponsor:
Information provided by (Responsible Party):
ProgenaBiome

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Surveys administered to subjects who have recovered from COVID-19 to assess how effective their treatment was.

Condition or disease Intervention/treatment
Covid19 COVID-19 Pneumonia COVID-19 Respiratory Infection COVID-19 Acute Bronchitis COVID-19 Acute Respiratory Distress Syndrome COVID-19 Lower Respiratory Infection SARS-CoV2 Infection SARS-CoV-2 Acute Respiratory Disease Other: No Intervention Used

Detailed Description:
Subjects who have recovered from COVID-19 will answer questions regarding the severity of their illness, symptoms experienced, what treatment they received, and how long they were ill.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 300 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: A Retrospective Study to Analyze Efficacy of COVID-19 Treatments
Actual Study Start Date : February 19, 2021
Estimated Primary Completion Date : February 28, 2022
Estimated Study Completion Date : July 31, 2022

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
COVID-19 Patients
Subjects who have recovered from COVID-19
 Other: No Intervention Used
There is no intervention in this study


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Survey Response [ Time Frame: One hour ]
    Answers given by subjects on their recovery from COVID-19


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Months and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
1. Refusal to sign informed consent form
Criteria

Inclusion Criteria:

  1. Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study
  2. Male or female of 18 years of age or older
  3. Diagnosis of COVID-19 infection by RT- PCR
  4. Recovery from COVID-19

Exclusion Criteria:

Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04949230


Contacts
Layout table for location contacts
Contact: Ginger Aurella 805-339-0549 ginger@progenabiome.com
Contact: Jordan E Daniels, MS 805-339-0549 jordan@progenabiome.com

Locations
Layout table for location information
United States, California
Ginger Aurella Recruiting
Ventura, California, United States, 93003
Contact: Ginger Aurella, MD    805-339-0549    ginger@progenabiome.com   
Contact: Jordan Daniels, MS    805-339-0549    jordan@progenabiome.com   
Principal Investigator: Sabine Hazan, MD         
Sponsors and Collaborators
ProgenaBiome
Investigators
Layout table for investigator information
Study Director: Sabine Hazan, MD ProgenaBiome
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: ProgenaBiome
ClinicalTrials.gov Identifier: NCT04949230    
Other Study ID Numbers: PRG-051
First Posted: July 2, 2021    Key Record Dates
Last Update Posted: September 5, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Infections
Communicable Diseases
COVID-19
Respiratory Tract Infections
Bronchitis
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Acute Lung Injury
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes
Pneumonia, Viral
Pneumonia
 Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiration Disorders
Infant, Premature, Diseases
Infant, Newborn, Diseases
Lung Injury
Bronchial Diseases
Lung Diseases, Obstructive